|
I'm not ed, but my best GUESS is sideways trading until the last interium Action I review is released in March or April Then depending on the data if favorable, study continues, sideways with a upward bias. If the study were to be terminateted, IMO unlikely, then the stock price declines very much. After the March April review release the only thing that will dirve the stock price, other then overal market, is news,i.e. final action results this summer ( July Aug) ESRD interium report, new clinical trial started, Idexx Lab. vet. filing, FDA filing on Action I clinical (dec98--Mar 99) |
